ICU脓毒症患者的临床亚型轨迹:一项观察性研究的二次分析
本研究为MARS与MIMIC-IV两个观察性危重脓毒症队列的二次分析,纳入入住ICU时符合Sepsis-3标准的患者,MARS 2416例、MIMIC-IV 10745例,并在入ICU时判定为四种先前识别的亚型之一。评估亚型在入ICU第2、4、7天的稳定性及变化,并分析亚型变化与结局、宿主反应改变的关系。结果显示亚型总体患病率在各时间点稳定,但个体患者亚型转换常见:第2天α型28-56%(MARS/MIMIC-IV)、β型33-71%、γ型57-32%、δ型50-48%发生转变;第4天总体亚型持续率为33-36%。第2、4、7天保持在或转为γ型的患者死亡率低于保持在或转为δ型者;反映炎症、凝血和内皮功能障碍的纵向宿主反应生物标志物在δ-δ组改变最大,其次为γ-δ组,且不依赖于天数或生物标志物类别。
要点
- 入住ICU时亚型分布:MARS中α型6%(n=150)、β型3%(n=70)、γ型55%(n=1317)、δ型36%(n=879);MIMIC-IV中α型22%(n=2398)、β型22%(n=2365)、γ型31%(n=3296)、δ型25%(n=2686)。
- 第2天亚型转换率:α型28-56%(MARS/MIMIC-IV)、β型33-71%、γ型57-32%、δ型50-48%;第4天总体亚型持续率33-36%。
- 第2、4、7天保持在或转为γ型的患者死亡率低于保持在或转为δ型者。
- 反映炎症、凝血和内皮功能障碍的纵向宿主反应生物标志物在δ-δ组改变最大,其次为γ-δ组,不依赖于天数或生物标志物类别。
- 作者认为,这些发现强调监测脓毒症亚型及其相关宿主反应对改善预后判断和个体化治疗策略的重要性。
适用人群与场景
- 入住ICU时符合Sepsis-3标准的患者,且可判定为四种先前识别的亚型之一;MARS队列2416例入住,MIMIC-IV队列10745例入住。
- 场景:荷兰与美国ICU,MARS为2011-2014年,MIMIC-IV为2008-2019年。
诊断标准与关键阈值
- 入住ICU时符合Sepsis-3标准。
- 亚型判定:入住ICU时判定为四种先前识别的亚型之一(α、β、γ、δ型)。
研究设计与关键结果
- 研究类型:两个观察性危重脓毒症队列(MARS与MIMIC-IV)的二次分析;MARS纳入2416例入住,MIMIC-IV纳入10745例入住。
- 入住ICU时亚型分布:MARS中α型6%(n=150)、β型3%(n=70)、γ型55%(n=1317)、δ型36%(n=879);MIMIC-IV中α型22%(n=2398)、β型22%(n=2365)、γ型31%(n=3296)、δ型25%(n=2686)。
- 亚型总体患病率在第2、4、7天稳定;但个体患者第2天转换率:α型28-56%(MARS/MIMIC-IV)、β型33-71%、γ型57-32%、δ型50-48%。
- 第4天总体亚型持续率为33-36%。
- 第2、4、7天保持在或转为γ型的患者死亡率低于保持在或转为δ型者。
- 反映炎症、凝血和内皮功能障碍的纵向宿主反应生物标志物在δ-δ组改变最大,其次为γ-δ组,不依赖于天数或生物标志物类别。
- 结论:在两个大型队列中,亚型向δ型转变与更差的临床结局及更异常的生物标志物相关。
证据类型、等级与局限
- 证据类型:观察性研究的二次分析(两个观察性危重脓毒症队列)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现强调监测脓毒症亚型及其相关宿主反应对改善预后判断和个体化治疗策略的重要性。
- 亚型向δ型转变与更差临床结局及更异常生物标志物相关,提示对转为δ型的患者可加强监测(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Sepsis is an evolving process and proposed subtypes may change over time. We hypothesized that previously established sepsis subtypes are dynamic, prognostic of outcome, and trajectories are associated with host response alterations.
DESIGN: A secondary analysis of two observational critically ill sepsis cohorts: the Molecular diAgnosis and Risk stratification of Sepsis (MARS) and the Medical Information Mart for Intensive Care-IV (MIMIC-IV).
SETTING: ICUs in the Netherlands and United States between 2011-2014 and 2008-2019, respectively.
PARTICIPANTS: Patient admission fulfilling the Sepsis-3 criteria upon ICU admission adjudicated to one of four previously identified subtypes, comprising 2,416 admissions in MARS and 10,745 in MIMIC-IV.
MAIN OUTCOMES AND MEASURES: Subtype stability and the changes per subtype on days 2, 4 and 7 of ICU admission were assessed. Next, the associated between change in clinical subtype and outcome and host response alterations.
RESULTS: In MARS, upon ICU admission, 6% (n = 150) of the patient admissions were α-type, 3% (n = 70) β-type, 55% (n = 1317) γ-type, and 36% (n = 879) δ-type; in MIMIC-IV, this was α = 22% (n = 2398), β = 22% (n = 2365), γ = 31% (n = 3296), and δ = 25% (2686). Overall, prevalence of subtypes was stable over days 2, 4, and 7. However, 28-56% (MARS/MIMIC-IV) changed from α on ICU admission to any of the other subtypes on day 2, 33-71% from β, 57-32% from γ, and 50-48% from δ. On day 4, overall subtype persistence was 33-36%. γ or δ admissions remaining in, or transitioning to, subtype γ on days 2, 4, and 7 exhibited lower mortality rates compared with those remaining in, or transitioning to, subtype δ. Longitudinal host response biomarkers reflecting inflammation, coagulation, and endothelial dysfunction were most altered in the δ-δ group, followed by the γ-δ group, independent of the day or biomarker domain.
CONCLUSIONS AND RELEVANCE: In two large cohorts, subtype change to δ was associated with worse clinical outcome and more aberrant biomarkers reflecting inflammation, coagulation, and endothelial dysfunction. These findings underscore the importance of monitoring sepsis subtypes and their linked host responses for improved prognostication and personalized treatment strategies.
参考来源
- Slim MA, van Amstel RBE, Müller MCA, et al. Clinical Subtype Trajectories in Sepsis Patients Admitted to the ICU: A Secondary Analysis of an Observational Study. Crit Care Explor. 2024. PMID: 39555471. doi:10.1097/CCE.0000000000001176
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。